Document Detail


Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
MedLine Citation:
PMID:  1788834     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Impaired fibrinolysis due to high plasminogen activator inhibitor levels is present in patients with a variety of thrombotic diseases. Plasminogen activator inhibitor levels correlate with triglyceride levels and are elevated in patients with hypertriglyceridemia. Treatment of asymptomatic hypertriglyceridemic patients with diet or medication results in improvement of fibrinolytic parameters. To determine if similar improvements in fibrinolysis occur during treatment of hypertriglyceridemia in patients with a history of venous thrombosis and impaired fibrinolysis due to high plasminogen activator inhibitor levels, 5 patients were given gemfibrozil. Triglyceride levels and fibrinolytic response to venous occlusion were determined before and after 30 days of treatment. Gemfibrozil therapy resulted in a predictable decrease in triglyceride levels in all patients, a reduction that was statistically significant (p = 0.04). There was no significant change in fibrinolytic variables during gemfibrozil therapy. Independent factors appear to control the plasminogen activator inhibitor and triglyceride levels in patients with a history of venous thrombosis.
Authors:
W D Haire
Related Documents :
6720724 - Unrecognized pulmonary embolism presenting as disseminated intravascular coagulation.
7378294 - Serum inhibitors of myelopoiesis.
1152504 - The hemostatic mechanism after open-heart surgery. i. studies on plasma coagulation fac...
6299654 - Angiotensin-converting enzyme in human adult respiratory distress syndrome.
17449234 - Systemic inflammation and systemic oxidative stress in patients with acute exacerbation...
23056774 - Acute hemorrhagic edema of infancy; a report of five iranian infants and review of the ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thrombosis research     Volume:  64     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1991 Nov 
Date Detail:
Created Date:  1992-03-20     Completed Date:  1992-03-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  493-501     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cholesterol / blood
Fibrinolysis / drug effects
Gemfibrozil / pharmacology*,  therapeutic use
Humans
Hypertriglyceridemia / blood,  complications,  drug therapy*
Plasminogen Inactivators / analysis*
Thrombophlebitis / complications*
Tissue Plasminogen Activator / analysis
Triglycerides / blood*
Chemical
Reg. No./Substance:
0/Plasminogen Inactivators; 0/Triglycerides; 25812-30-0/Gemfibrozil; 57-88-5/Cholesterol; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Circadian variations of platelet aggregability and fibrinolytic activity in patients with ischemic s...
Next Document:  Temperature-dependence of LDL binding and activation of human platelets.